[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100468116":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":73,"collaborators":75,"id":92,"slug":93,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":94,"sex":100,"minAge":101,"maxAge":10,"enrollmentInfo":102,"targetDuration":10,"studyType":105,"phases":10,"briefSummary":106,"conditions":107,"keywords":10,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Royal Marsden NHS Foundation Trust","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Benign Nodules",null,"CT scans of patients with a new lung nodule(s) subsequently confirmed to be benign and in the context of a previous history of radically treated cancer, will be identified at participating NHS sites and recruited.",[13],"Other: Non-Interventional Study",{"label":15,"type":10,"description":16,"interventionNames":17},"Metastatic Nodules","CT scans of patients with a new lung nodule(s) subsequently confirmed to be metastatic in nature and in the context of a previous history of radically treated cancer, will be identified at participating NHS sites and recruited.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Second Primary Lung Cancers","CT scans of patients with a new lung nodule(s) subsequently confirmed to be a new second primary lung cancer and in the context of a previous history of radically treated cancer, will be identified at participating NHS sites and recruited.",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Non-Interventional Study","First nodule detection CT scans as per eligibility criteria will be used as input into in-house software to extract multiple radiomic features and used to develop a machine learning based classifier to differentiate nodule aetiology. Scans will also be used as input in to a deep learning\u002Fconvolutional neural network models to perform automated imaging classification.",[9,15,19],[28],{"name":29,"affiliation":30,"role":31},"Richard Lee","The Royal Marsden Hospitals NHS Trust","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Sejal Jain","CONTACT","020 7808 2603","sejal.jain@rmh.nhs.uk",{"name":39,"role":35,"phone":36,"phoneExt":10,"email":40},"Laura Boddy","laura.boddy@rmh.nhs.uk",[42,61],{"facility":43,"status":44,"city":45,"state":10,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"The Royal Marsden NHS Foundation Trust (Chelsea Site)","RECRUITING","London","SW3 6JJ","United Kingdom","UK",{"type":50,"coordinates":51},"Point",[52,53],-0.12574,51.50853,{"lat":53,"lon":52},[56,58,60],{"name":34,"role":35,"phone":57,"phoneExt":10,"email":37},"02078082603",{"name":39,"role":35,"phone":59,"phoneExt":10,"email":40},"07414643915",{"name":29,"role":31,"phone":10,"phoneExt":10,"email":10},{"facility":62,"status":44,"city":45,"state":10,"zip":63,"country":47,"countryCode":48,"cosmosGeoPoint":64,"geoPoint":66,"contacts":67},"Royal Brompton Hospital","SW3 6NP",{"type":50,"coordinates":65},[52,53],{"lat":53,"lon":52},[68,71],{"name":69,"role":35,"phone":57,"phoneExt":10,"email":70},"Hardeep Kalsi","hardeep.kalsi@rmh.nhs.uk",{"name":72,"role":31,"phone":10,"phoneExt":10,"email":10},"Anand Deveraj",{"type":74,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[76,78,81,83,86,88,90],{"name":77,"class":6},"Institute of Cancer Research, United Kingdom",{"name":79,"class":80},"National Institute for Health Research, United Kingdom","OTHER_GOV",{"name":82,"class":6},"Royal Brompton & Harefield NHS Foundation Trust",{"name":84,"class":85},"Royal Marsden Partners Cancer Alliance","UNKNOWN",{"name":87,"class":6},"Imperial College London",{"name":89,"class":6},"Oxford University Hospitals NHS Trust",{"name":91,"class":6},"National Heart and Lung Institute","100468116","ai--radiomics-for-stratification-of-lung-nodules-after-radically-treated-cancer-100468116",false,"NCT05375591","AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer","Artificial Intelligence & Radiomics for Stratification Of Lung Nodules After Radically Treated Cancer (AI-SONAR)","AI-SONAR","Inclusion Criteria:\n\n* Confirmed history of previous radically or curative-intent treated solid organ cancer within 10 years of new index CT thoracic scan demonstrating a new pulmonary nodule and either of the following:\n\n  * Biopsy confirming previous malignancy with MDT consensus and successful cancer resolution\u002Fremission following anti-cancer treatment on interval imaging or blood assay analysis\n  * Where biopsy was not possible\u002Fconfirmed for previous malignancy, MDT consensus outcome confirming cancer (+\u002F- calculated Herder score \\>80% if applicable) and decision to treat as malignancy with subsequent resolution\u002Fremission following anti-cancer treatment on interval imaging or blood assay analysis\n* Radical treatment for previous cancer defined as either of the following:\n\n  * Surgical resection\n  * Radical radiotherapy or stereotactic beam radiotherapy\n  * Radical chemotherapy\n  * Radical chemo-radiotherapy\n  * Multi-modality treatment with any of the above\n* New pulmonary nodule ground truth known\n\n  * Scan data showing 2-year stability (based on diameter or volumetry) or resolution in cases of benign disease\n  * Scan data showing progressive nodule enlargement or increase in nodule number on interval imaging with MDT consensus (+\u002F- PET with Herder score \\>80% if applicable) determining metastatic disease or new primary malignancy\n  * Biopsy sampling confirming benign disease or malignancy and in cases of malignancy, metastasis or new primary lung cancer\n* CT scan slice thickness ≤ 2.5mm\n* Nodule size ≥ 5mm\n\nExclusion Criteria:\n\n* CT Imaging \\> 10 years old\n* Non-solid haematological malignancies including leukaemia\n* Cases of radically treated primary cancer disease with early oligometastatic recurrence treated radically","ALL","18 Years",{"count":103,"type":104},1000,"ESTIMATED","OBSERVATIONAL","This study will assess the utility of radiomics and artificial intelligence approaches to new lung nodules in patients who have undergone radical treatment for a previous cancer.",[108,109,110,111],"Indeterminate Pulmonary Nodules","Lung Metastases","Second Primary Cancer","Lung Cancer","2022-05-17",{"date":114,"type":115},"2022-05-24","ACTUAL",{"date":117,"type":115},"2021-10-13",{"date":119,"type":104},"2026-11-01",{"name":5,"class":6},2]